Cargando…

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates

Omicron SARS-CoV-2 variants escape vaccine-induced neutralizing antibodies and cause nearly all current COVID-19 cases. Here, we compared the efficacy of three booster vaccines against Omicron BA.5 challenge in rhesus macaques: mRNA-1273, the Novavax ancestral spike protein vaccine (NVX-CoV2373), or...

Descripción completa

Detalles Bibliográficos
Autores principales: Routhu, Nanda Kishore, Stampfer, Samuel David, Lai, Lilin, Akhtar, Akil, Tong, Xin, Yuan, Dansu, Chicz, Taras M., McNamara, Ryan P., Jakkala, Kishor, Davis-Gardner, Meredith E., St Pierre, E. Lovisa, Smith, Brandon, Green, Kristyn Moore, Golden, Nadia, Picou, Breanna, Jean, Sherrie M., Wood, Jennifer, Cohen, Joyce, Moore, Ian N., Patel, Nita, Guebre-Xabier, Mimi, Smith, Gale, Glenn, Greg, Kozlowski, Pamela A., Alter, Galit, Ahmed, Rafi, Suthar, Mehul S., Amara, Rama Rao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451060/
https://www.ncbi.nlm.nih.gov/pubmed/37191508
http://dx.doi.org/10.1126/sciimmunol.adg7015
_version_ 1785095344570236928
author Routhu, Nanda Kishore
Stampfer, Samuel David
Lai, Lilin
Akhtar, Akil
Tong, Xin
Yuan, Dansu
Chicz, Taras M.
McNamara, Ryan P.
Jakkala, Kishor
Davis-Gardner, Meredith E.
St Pierre, E. Lovisa
Smith, Brandon
Green, Kristyn Moore
Golden, Nadia
Picou, Breanna
Jean, Sherrie M.
Wood, Jennifer
Cohen, Joyce
Moore, Ian N.
Patel, Nita
Guebre-Xabier, Mimi
Smith, Gale
Glenn, Greg
Kozlowski, Pamela A.
Alter, Galit
Ahmed, Rafi
Suthar, Mehul S.
Amara, Rama Rao
author_facet Routhu, Nanda Kishore
Stampfer, Samuel David
Lai, Lilin
Akhtar, Akil
Tong, Xin
Yuan, Dansu
Chicz, Taras M.
McNamara, Ryan P.
Jakkala, Kishor
Davis-Gardner, Meredith E.
St Pierre, E. Lovisa
Smith, Brandon
Green, Kristyn Moore
Golden, Nadia
Picou, Breanna
Jean, Sherrie M.
Wood, Jennifer
Cohen, Joyce
Moore, Ian N.
Patel, Nita
Guebre-Xabier, Mimi
Smith, Gale
Glenn, Greg
Kozlowski, Pamela A.
Alter, Galit
Ahmed, Rafi
Suthar, Mehul S.
Amara, Rama Rao
author_sort Routhu, Nanda Kishore
collection PubMed
description Omicron SARS-CoV-2 variants escape vaccine-induced neutralizing antibodies and cause nearly all current COVID-19 cases. Here, we compared the efficacy of three booster vaccines against Omicron BA.5 challenge in rhesus macaques: mRNA-1273, the Novavax ancestral spike protein vaccine (NVX-CoV2373), or Omicron BA.1 spike protein version (NVX-CoV2515). All three booster vaccines induced a strong BA.1 cross-reactive binding antibody and changed immunoglobulin G dominance from IgG1 to IgG4 in the serum. All three booster vaccines also induced strong and comparable neutralizing antibody responses against multiple variants of concern, including BA.5 and BQ.1.1, along with long-lived plasma cells in the bone marrow. The ratio of BA.1 to WA-1 spike-specific antibody-secreting cells in the blood was higher in NVX-CoV2515 animals compared to NVX-CoV2373 animals, suggesting a better recall of BA.1 specific memory B cells by the BA.1 spike-specific vaccine compared to the ancestral spike-specific vaccine. Further, all three booster vaccines induced low levels of spike-specific CD4 but not CD8 T cell responses in the blood. Following challenge with SARS-CoV-2 BA.5 variant, all three vaccines showed strong protection in the lungs and controlled virus replication in the nasopharynx. In addition, both Novavax vaccines blunted viral replication in nasopharynx at day 2. The protection against SARS-CoV-2 BA.5 infection in the upper respiratory airways correlated with binding, neutralizing, and ADNP activities of the serum antibody. These data have important implications for COVID-19 vaccine development, as vaccines that lower nasopharyngeal virus may help to reduce transmission.
format Online
Article
Text
id pubmed-10451060
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-104510602023-09-11 Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates Routhu, Nanda Kishore Stampfer, Samuel David Lai, Lilin Akhtar, Akil Tong, Xin Yuan, Dansu Chicz, Taras M. McNamara, Ryan P. Jakkala, Kishor Davis-Gardner, Meredith E. St Pierre, E. Lovisa Smith, Brandon Green, Kristyn Moore Golden, Nadia Picou, Breanna Jean, Sherrie M. Wood, Jennifer Cohen, Joyce Moore, Ian N. Patel, Nita Guebre-Xabier, Mimi Smith, Gale Glenn, Greg Kozlowski, Pamela A. Alter, Galit Ahmed, Rafi Suthar, Mehul S. Amara, Rama Rao Sci Immunol Research Articles Omicron SARS-CoV-2 variants escape vaccine-induced neutralizing antibodies and cause nearly all current COVID-19 cases. Here, we compared the efficacy of three booster vaccines against Omicron BA.5 challenge in rhesus macaques: mRNA-1273, the Novavax ancestral spike protein vaccine (NVX-CoV2373), or Omicron BA.1 spike protein version (NVX-CoV2515). All three booster vaccines induced a strong BA.1 cross-reactive binding antibody and changed immunoglobulin G dominance from IgG1 to IgG4 in the serum. All three booster vaccines also induced strong and comparable neutralizing antibody responses against multiple variants of concern, including BA.5 and BQ.1.1, along with long-lived plasma cells in the bone marrow. The ratio of BA.1 to WA-1 spike-specific antibody-secreting cells in the blood was higher in NVX-CoV2515 animals compared to NVX-CoV2373 animals, suggesting a better recall of BA.1 specific memory B cells by the BA.1 spike-specific vaccine compared to the ancestral spike-specific vaccine. Further, all three booster vaccines induced low levels of spike-specific CD4 but not CD8 T cell responses in the blood. Following challenge with SARS-CoV-2 BA.5 variant, all three vaccines showed strong protection in the lungs and controlled virus replication in the nasopharynx. In addition, both Novavax vaccines blunted viral replication in nasopharynx at day 2. The protection against SARS-CoV-2 BA.5 infection in the upper respiratory airways correlated with binding, neutralizing, and ADNP activities of the serum antibody. These data have important implications for COVID-19 vaccine development, as vaccines that lower nasopharyngeal virus may help to reduce transmission. American Association for the Advancement of Science 2023-05-16 /pmc/articles/PMC10451060/ /pubmed/37191508 http://dx.doi.org/10.1126/sciimmunol.adg7015 Text en Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Routhu, Nanda Kishore
Stampfer, Samuel David
Lai, Lilin
Akhtar, Akil
Tong, Xin
Yuan, Dansu
Chicz, Taras M.
McNamara, Ryan P.
Jakkala, Kishor
Davis-Gardner, Meredith E.
St Pierre, E. Lovisa
Smith, Brandon
Green, Kristyn Moore
Golden, Nadia
Picou, Breanna
Jean, Sherrie M.
Wood, Jennifer
Cohen, Joyce
Moore, Ian N.
Patel, Nita
Guebre-Xabier, Mimi
Smith, Gale
Glenn, Greg
Kozlowski, Pamela A.
Alter, Galit
Ahmed, Rafi
Suthar, Mehul S.
Amara, Rama Rao
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
title Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
title_full Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
title_fullStr Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
title_full_unstemmed Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
title_short Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
title_sort efficacy of mrna-1273 and novavax ancestral or ba.1 spike booster vaccines against sars-cov-2 ba.5 infection in non-human primates
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451060/
https://www.ncbi.nlm.nih.gov/pubmed/37191508
http://dx.doi.org/10.1126/sciimmunol.adg7015
work_keys_str_mv AT routhunandakishore efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT stampfersamueldavid efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT laililin efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT akhtarakil efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT tongxin efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT yuandansu efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT chicztarasm efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT mcnamararyanp efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT jakkalakishor efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT davisgardnermeredithe efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT stpierreelovisa efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT smithbrandon efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT greenkristynmoore efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT goldennadia efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT picoubreanna efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT jeansherriem efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT woodjennifer efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT cohenjoyce efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT mooreiann efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT patelnita efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT guebrexabiermimi efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT smithgale efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT glenngreg efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT kozlowskipamelaa efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT altergalit efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT ahmedrafi efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT sutharmehuls efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates
AT amararamarao efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates